Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ligelizumab - Novartis

Next Previous
Drug Profile

Ligelizumab - Novartis

Alternative Names: QGE-031

Latest Information Update: 13 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tanox
  • Developer Novartis
  • Class Anti-inflammatories; Antiallergics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Immunoglobulin E inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Peanut hypersensitivity
  • Discontinued Allergic asthma; Atopic dermatitis; Bullous pemphigoid; Chronic urticaria; Food hypersensitivity; Hypersensitivity

Most Recent Events

  • 19 Mar 2025 Novartis terminates phase-III trial in Food hypersensitivity (In children, In adults, In adolescents) in USA, Spain, Netherlands, Japan, Italy, Germany, France, Canada, Australia (SC) due to sponsor decision (NCT05678959)
  • 05 Apr 2023 Discontinued - Phase-II for Chronic-urticaria (In adolescents, In children) in Taiwan, Switzerland, Spain, Germany (SC) before March 2023
  • 05 Apr 2023 Discontinued - Phase-III for Chronic-urticaria (In adolescents, In children, In the elderly, Treatment-experienced, In adults) in Brazil (SC) before March 2023

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top